Adoptive immunotherapy is when a patient receives extra functioning immune cells grown from his/her own body (autologous cell therapy) or taken from a compatible donor (allogeneic cell therapy). In the fight against cancer, allogeneic cell therapy offers something the conventional autologous approach cannot: the potential to treat large numbers of patients using a standardized, off the shelf therapeutic product.
Derived from a genetically different recipient. Cellectis’ gene-editing technologies allow us to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves.
Derived from part of the same individual.